Skip to main content
Cybin Inc. logo

Cybin Inc. - Investor Relations & Filings

Listed IPO Sep 2019
Ticker · HELP ISIN · CA23256X4075 LEI · 549300NTYWN4CVYSCN32 NEO Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2026-07-16 Regulatory Filings
Country CA Canada
Listing NEO HELP · 9 venues

Key figures FY2025

Period ended 2025-03-31 · CAD
Headline annual figures for Cybin Inc., fiscal year 2025, reported in CAD, with the source filing for each figure.
Net Income CAD -113.14M per the Audit Report / Information filed 2025-07-01
Total Assets CAD 258.62M per the Audit Report / Information filed 2025-07-01
Total Equity CAD 237.20M per the Audit Report / Information filed 2025-07-01
Cash from Ops CAD -101.30M per the Audit Report / Information filed 2025-07-01

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Cybin Inc.

http://www.cybin.com

Cybin Inc. is a clinical-stage biopharmaceutical company specializing in breakthrough neuropsychiatry, committed to developing next-generation therapeutics to revolutionize mental healthcare. The company utilizes proprietary drug discovery platforms to innovate Novel Serotonergic Agonists (NSAs)—synthetic molecules designed to activate serotonin pathways and promote neuroplasticity—paired with precision drug delivery systems. A core technological differentiator is the use of deuteration technology to create treatments with consistent delivery and commercial scalability. Cybin maintains a robust intellectual property portfolio, including over 100 granted patents and 250 pending applications, supporting its active drug programs, such as CYB004, currently in Phase 2 clinical trials for the treatment of Generalized Anxiety Disorder. The mission is to provide treatments designed to foster durable improvements in mental health.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC. It is a short regulatory filing (1,391 characters) that serves as a cover for an exhibit (a Material Change Report) and includes a signature page and incorporation by reference statement. It does not contain the actual financial statements or the substantive content of the referenced report, but rather acts as a formal regulatory submission. Per the rules, Form 6-K filings that act as cover documents or regulatory notifications without containing the primary financial report data are classified as RNS.
2026-07-16 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Cybin Inc., dated June 29, 2026. Form 6-Ks are used to furnish information that is of importance to the SEC but are not annual or interim reports (which would be Form 20-F or 40-F for foreign issuers). The document is short (1394 characters) and primarily contains a cover page, signature, and an exhibit index referencing a news release. It does not contain financial statements or detailed financial data, nor is it a transcript or management discussion. It is therefore a regulatory filing that does not fit into more specific categories like annual reports, earnings releases, or others. Hence, this document is best classified under Regulatory Filings (RNS).
2026-06-29 English
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the closing of a US$50 million underwritten offering of common shares. It details the number of shares sold, the offering price, the use of proceeds, and the underwriters involved. This falls under the category of capital raising and financing activities, which is explicitly defined as 'Capital/Financing Update' (CAP).
2026-06-25 English
6-K
Regulatory Filings Classification · 100% confidence The document is identified as a Form 6-K filed with the SEC, which is a report of a foreign private issuer pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. It is short (1152 characters) and mainly contains signature and identification information. It references an exhibit index with a news release but does not contain detailed financial performance, management discussion, or other substantive report content typical of Annual Reports or Interim Reports. Given its nature and length, it is a regulatory filing notifying the filing or presence of certain information rather than the report itself. Therefore, it best matches the Regulatory Filings (RNS) category.
2026-06-25 English
Marketing materials (other than specified derivative) - English.pdf
Regulatory Filings Classification · 95% confidence The document is a 'Free Writing Prospectus' filed pursuant to Rule 433, which is a specific type of regulatory filing used by companies to communicate information about an offering of securities. While it contains an update on clinical trial progress, the primary legal nature of the document is a prospectus supplement/offering communication rather than a standard earnings release or financial report. Given the specific regulatory context and the nature of the content, it falls under the broader category of Regulatory Filings.
2026-06-24 English
Consent letter of issuer's legal counsel.pdf
Regulatory Filings Classification · 100% confidence The document is a legal consent letter from the issuer's legal counsel (Aird & Berlis LLP) regarding a Prospectus Supplement. It is a regulatory filing required by securities commissions to confirm the inclusion of legal opinions and firm references in a prospectus. It does not contain financial statements, earnings data, or management analysis, and it is not a report itself, but rather a supporting regulatory document. Therefore, it falls under the fallback category of Regulatory Filings (RNS).
2026-06-24 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.